Skip to content
10-Q

Quarterly Report

Kite Pharma, Inc.

0001510580-17-000011

← back to feed
Filed
Aug 8, 2017 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2017 · Aug 4, 2017 57.18M sh
Capex Q2 2017 · Jun 30, 2017 $5.6M
Capex Q2 2017 · Jun 30, 2016 $13.78M
Cash And Equivalents Q2 2017 · Jun 30, 2017 $147.84M
Cash And Equivalents Q2 2017 · Dec 31, 2016 $114.56M
Cash And Equivalents Q2 2017 · Jun 30, 2016 $170.16M
Cash And Equivalents Q2 2017 · Dec 31, 2015 $392.84M
Stockholders Equity Q2 2017 · Jun 30, 2017 $709.25M
Stockholders Equity Q2 2017 · Dec 31, 2016 $427.97M
Current Liabilities Q2 2017 · Jun 30, 2017 $88.56M
Current Liabilities Q2 2017 · Dec 31, 2016 $55.14M
Total Liabilities Q2 2017 · Jun 30, 2017 $197.86M
Total Liabilities Q2 2017 · Dec 31, 2016 $96.33M
Current Assets Q2 2017 · Jun 30, 2017 $798.28M
Current Assets Q2 2017 · Dec 31, 2016 $427.4M
Total Assets Q2 2017 · Jun 30, 2017 $907.11M
Total Assets Q2 2017 · Dec 31, 2016 $524.3M
Sga Expense Q2 2017 · Jun 30, 2017 $41.1M
Sga Expense Q2 2017 · Jun 30, 2017 $76.47M
Sga Expense restated Q2 2017 · Jun 30, 2016 $23.71M
Sga Expense restated Q2 2017 · Jun 30, 2016 $40.4M
Rd Expense Q2 2017 · Jun 30, 2017 $70.87M
Rd Expense Q2 2017 · Jun 30, 2017 $136.78M
Rd Expense Q2 2017 · Jun 30, 2016 $47.36M
Rd Expense Q2 2017 · Jun 30, 2016 $81.77M
Net Income Q2 2017 · Jun 30, 2017 −$109.82M
Net Income Q2 2017 · Jun 30, 2017 −$200.22M
Net Income Q2 2017 · Jun 30, 2016 −$64.27M
Net Income Q2 2017 · Jun 30, 2016 −$108.19M
Operating Income Q2 2017 · Jun 30, 2017 −$101.92M
Operating Income Q2 2017 · Jun 30, 2017 −$193.36M
Operating Income restated Q2 2017 · Jun 30, 2016 −$66.27M
Operating Income restated Q2 2017 · Jun 30, 2016 −$112.24M
Revenue Q2 2017 · Jun 30, 2017 $10.05M
Revenue Q2 2017 · Jun 30, 2017 $19.89M
Revenue Q2 2017 · Jun 30, 2016 $4.8M
Revenue Q2 2017 · Jun 30, 2016 $9.92M